

## Literatura ACTA MEDICINAE 5–7/2022 Gynekologie | Onkogynekologie | Urologie

- 2 **Isoprinosin snižuje recidivy cervikální dysplazie a prekanceróz způsobených HPV infekcí**  
doc. MUDr. Jiří Slíva, Ph.D. Ústav farmakologie, 3. LF UK, Praha
- 2 **Očkování HPV u dospělých. Zpráva ze satelitního sympozia MSD na EUROGIN 2022**  
doc. MUDr. Tomáš Fait, Ph.D. Gynekologicko-porodnická klinika 2. LF UK a FN v Motole, Praha
- 2 **Léčebné možnosti HER2 pozitivního metastatického karcinomu prsu**  
MUDr. Miloš Holánek, Ph.D. Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno
- 2 **Niraparib v udržovací léčbě pokročilého karcinomu vaječníků – kazuistika**  
prof. MUDr. Michal Zikán, Ph.D. Gynekologicko-porodnická klinika 1. LF UK a Fakultní nemocnice Bulovka, Praha
- 2 **Imunoterapie v léčbě karcinomu děložního hrdla a endometria**  
prof. MUDr. Michal Zikán, Ph.D. Gynekologicko-porodnická klinika 1. LF UK a Fakultní nemocnice Bulovka, Praha
- 3 **Prevence recidivujících infekcí močových cest bakteriálními lyzáty**  
doc. MUDr. Peter Koliba, CSc. Gynekologická ambulance Gynartis, s. r. o., Ostrava
- 3 **První klinické zkušenosti s pivmecilinamem v terapii nekomplikovaných infekcí dolních močových cest – kazuistika**  
prof. MUDr. Jan Krhut, Ph.D. Urologická klinika FN Ostrava, Katedra chirurgických oborů LF OU, Ostrava
- 4 **Hyperaktivní močový měchýř – farmakologické možnosti léčby**  
MUDr. Marek Gojdič, Ph.D. UROGYN MEDICO, privátní urologická klinika, Urologické oddělení Fakultní nemocnice Bulovka, Praha  
MUDr. Miroslava Ryšánková, privátní urologická ambulance Náchod
- 4 **Komplexní léčba gynekologických zánětů**  
MUDr. Jana Kadlecová Gynekologicko-porodnická klinika LF MU a FN Brno
- 4 **Současné možnosti terapie vulvovaginální kandidózy**  
doc. MUDr. Petr Hamal, Ph.D. | MDDr. Lucie Svobodová, Ph.D. Ústav mikrobiologie LF UP a FN Olomouc
- 4 **Farmakologická léčba mimoděložního těhotenství**  
MUDr. Borek Sehnal, Ph.D. Gynekologicko-porodnická klinika, Fakultní nemocnice Bulovka a 1. LF UK, Praha, Nemocnice Neratovice  
MUDr. Peter Koliba Gynekologicko-porodnická klinika, Fakultní nemocnice Bulovka a 1. LF UK, Praha
- 5 **Pilotní projekt časného záchytu tyreopatií v graviditě**  
MUDr. Marcela Koudelková | Mgr. Renata Chloupková | Mgr. Jan Kouřil | Mgr. Ondřej Ngo | PhDr. Karel Hejduk |  
prof. RNDr. Ladislav Dušek, Ph.D. | RNDr. Ondřej Májek, Ph.D. Národní screeningové centrum, Ústav zdravotnických informací a statistiky ČR, Praha, Institut biostatistiky a analýz, LF MUNI, Brno  
doc. MUDr. Jan Jiskra, Ph.D. | doc. MUDr. Zdenka Límanová, CSc. III. interní klinika 1. LF UK a VFN, Praha  
doc. Ing. Drahomíra Springer, Ph.D. Ústav lékařské biochemie a laboratorní diagnostiky 1. LF UK a VFN, Praha
- 5 **Očkování v těhotenství**  
doc. MUDr. Michal Koucký, Ph.D. Gynekologicko-porodnická klinika 1. LF UK a VFN, Praha
- 5 **Covid-19 a těhotenství**  
MUDr. Simona Mlezivová | prof. MUDr. Michal Zikán, Ph.D. Gynekologicko-porodnická klinika 1. LF UK a Fakultní nemocnice Bulovka, Praha
- 6 **Význam moderních přístupů k suplementaci železa pro zdravé ženy**  
doc. MUDr. Tomáš Fait, Ph.D. Gynekologicko-porodnická klinika 2. LF UK a FN v Motole, Praha
- 6 **Klinické použití mikronizovaného progesteronu**  
MUDr. Petr Křepelka, Ph.D. Ústav pro péči o matku a dítě, Praha
- 6 **Cholin jako esenciální živina a jeho význam v těhotenství**  
MUDr. Simona Mlezivová Gynekologicko-porodnická klinika 1. LF UK a Fakultní nemocnice Bulovka, Praha  
prof. MUDr. Pavel Calda, CSc. Centrum fetální medicíny, Gynekologicko-porodnická klinika 1. LF UK a VFN, Praha
- 7 **Sildenafil možným přínosem v léčbě Alzheimerovy choroby?**  
doc. MUDr. Jiří Slíva, Ph.D. Ústav farmakologie, 3. LF UK, Praha

# Isoprinosin snižuje recidivy cervikální dysplazie a prekanceróz způsobených HPV infekcí

doc. MUDr. Jiří Slíva, Ph.D. Ústav farmakologie, 3. LF UK, Praha

- 1 Farahmand, M. – Moghoofoei, M. – Dorost, A., et al.: Prevalence and genotype distribution of genital human papillomavirus infection in female sex workers in the world: a systematic review and meta-analysis. *BMC Public Health*, 2020, 20, s. 1455.
- 2 Franco, E. L. – Villa, L. L. – Sobrinho, J. P., et al.: Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. *J Infect Dis*, 1999, 180, s. 1415–1423.
- 3 WHO. International Agency for Research on Cancer (IARC). IARC Monograph. Volume 100-B. Biological Agents. „Human Papillomaviruses – Epidemiology“. Published by the International Agency for Research on Cancer. Geneva 27, Switzerland: WHO Press, World Health Organization; 2012, s. 255–313.
- 4 Dugué, P. A. – Rebolj, M. – Garred, P. – Lynge, E.: Immunosuppression and risk of cervical cancer. *Expert Rev Anticancer Ther*, 2013, 13, s. 29–42.
- 5 Conesa-Zamora, P.: Immune responses against virus and tumor in cervical carcinogenesis: treatment strategies for avoiding the HPV-induced immune escape. *Gynecol Oncol*, 2013, 131, s. 480–488.
- 6 Zhou, C. – Tuong, Z. K. – Frazer, I. H.: Papillomavirus immune evasion strategies target the infected cell and the local immune system. *Front Oncol*, 2019, 9, s. 682.
- 7 Kovachev, S.: Immunotherapy in patients with local HPV infection and high-grade squamous intra epithelial lesion following uterine cervical conization. *Immunopharmacol Immune Toxicol*, 2020, 42, s. 314–318.
- 8 Bascones-Martinez, A. – Mattila, R. – Gomez-Font, R., et al.: Immunomodulatory drugs: oral and systemic adverse effects. *Med Oral Patol Oral Cir Bucal*, 2014, 19, s. e24–e31.
- 9 Ahmed, R. S. – Newman, A. S. – O'Daly, J., et al.: Inosine acedoben dimepranol promotes an early and sustained increase in the natural killer cell component of circulating lymphocytes: A clinical trial supporting anti-viral indications. *Int Immunopharmacol*, 2017, 42, s. 108–114.
- 10 Sliva, J. – Pantartzis, C. N. – Votava, M.: Inosine pranobex: a key player in the game against a wide range of viral infections and non-infectious diseases. *Adv Ther*, 2019, 36, s. 1878–1905.
- 11 Sadoul, G. – Beuret, T. H.: Treatment of cervical and vulvar condylomata by CO<sub>2</sub> laser also with an immunostimulant. *Rev Fran Gynecol Obstet*, 1984, 79, s. 681–684.
- 12 Mohanty, K. C. – Scott, C. S.: Immunotherapy of genital warts with inosine pranobex (Imunovir): preliminary study. *Sex Transm Infect*, 1986, 62, s. 352–355.
- 13 Davidson-Parker, J. – Dinsmore, W. – Khan, M. H., et al.: Immunotherapy of genital warts with inosine pranobex and conventional treatment: double blind placebo controlled study. *Genitourin Med*, 1988, 64, s. 383–386.
- 14 Nejmark, B. A. – Kondrateva, J. S. – Zologina, V. S.: Effectiveness of combined treatment of HPV infection. *Urologia*, 2015, 2, s. 39–42.
- 15 Tay, S. K.: Efficacy of inosine pranobex oral therapy in subclinical human papillomavirus infection of the vulva: a randomized double-blinded placebo controlled study. *Int J STD AIDS*, 1996, 7, s. 276–280.
- 16 Pestrikova, T. Y. – Pushkar, V. A.: Evaluation of comprehensive treatment of cervical pathology associated with HPV. *Gynecol*, 2015, 17, s. 50–53.
- 17 Kedrova, A. G. – Podisov, Y. I. – Kuznetsov, V. V., et al.: Role of antiviral therapy in the complex treatment of patients with epithelial dysplasias and preinvasive cancer of the cervix uteri. *Akush Ginekol*, 2006, 6, s. 27–30.
- 18 Kovachev, S.: Immunotherapy in patients with local HPV infection and high-grade squamous intra epithelial lesion following uterine cervical conization. *Immunopharmacol Immunotoxicol*, 2020, 42, s. 314–318.

## Očkování HPV u dospělých. Zpráva ze satelitního sympozia MSD na EUROGIN 2022

doc. MUDr. Tomáš Fait, Ph.D. Gynekologicko-porodnická klinika 2. LF UK a FN v Motole, Praha

- 1 Joura, E. A. – Garland, S. M. – Paavonen, J., et al.: Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data. *BMJ*, 2012, 344, s. e1401.
- 2 Kang, W. D. – Choi, H. S. – Kim, S. M.: Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade cervical intraepithelial neoplasia (CIN2-3)? *Gynecol Oncol*, 2013, 130, s. 264–268.
- 3 Ghelardi, A. – Parazzini, F. – Martella, F., et al.: SPERANZA project: HPV vaccination after treatment for CIN2. *Gynecol Oncol*, 2018, 151, s. 229–234.

## Léčebné možnosti HER2 pozitivního metastatického karcinomu prsu

MUDr. Miloš Holánek, Ph.D. Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno

- 1 Smith, I. E.: Efficacy and safety of Herceptin in women with metastatic breast cancer: results from pivotal clinical studies. *Anticancer Drugs*, 2001, 12, suppl. 4, s. S3–S10.
- 2 Slamon, D. J. – Leyland-Jones, B. – Shak, S., et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. *N Engl J Med*, 2001, 344, s. 783–92.
- 3 Marty, M. – Cognetti, F. – Maraninchi, D., et al.: Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. *J Clin Oncol*, 2005, 23, s. 4265–4274.
- 4 Baselga, J. – Cortés, J. – Kim, S. B., et al.: Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. *N Engl J Med*, 2012, 366, s. 109–119.
- 5 Verma, S. – Miles, D. – Gianni, L., et al.: Trastuzumab emtansine for HER2-positive advanced breast cancer. *N Engl J Med*, 2012, 367, s. 1783–1791.
- 6 Geyer, C. E. – Forster, J. – Lindquist, D., et al.: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. *N Engl J Med*, 2006, 355, s. 2733–2743.
- 7 Schwartzberg, L. S. – Franco, S. X. – Florence, A., et al.: Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer. *Oncologist*, 2010, 15, s. 122–129.
- 8 Doss, S. – Robertson, J. – Adam, J.: Lapatinib or trastuzumab in combination with an aromatase inhibitor for first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2. *Lancet Oncol*, 2012, 13, s. 766–767.
- 9 Fleeman, N. – Bagust, A. – Boland, A., et al.: Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysis. *Health Technol Assess*, 2011, 15, s. 1–93, iii–iv.
- 10 Wu, Y. – Amonkar, M. M. – Sherrill, B. H., et al.: Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer. *Ann Oncol*, 2011, 22, s. 2582–2590.
- 11 Murthy, R. K. – Loi, S. – Okines, A., et al.: Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. *N Engl J Med*, 2020, 382, s. 597–609.
- 12 Modi, S. – Saura, C. – Yamashita, T., et al.: Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. *N Engl J Med*, 2020, 382, s. 610–621.
- 13 Cortés, J. – Kim, S. B. – Chung, W. P., et al.: Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. *N Engl J Med*, 2022, 386, s. 1143–1154.
- 14 Gennari, A. – André, F. – Barrios, C. H., et al.: ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. *Ann Oncol*, 2021, 32, s. 1475–1495.

## Niraparib v udržovací léčbě pokročilého karcinomu vaječníků – kazuistika

prof. MUDr. Michal Zikán, Ph.D. Gynekologicko-porodnická klinika 1. LF UK a Fakultní nemocnice Bulovka, Praha

- 1 González-Martín, A. – Pothuri, B. – Vergote, I., et al.: PRIMA/ENGOT-OV26/GOG-3012 Investigators: Niraparib in patients with newly diagnosed advanced ovarian cancer. *N Engl J Med*, 2019, 381, s. 2391–2402.

## Imunoterapie v léčbě karcinomu děložního hrdla a endometria

prof. MUDr. Michal Zikán, Ph.D. Gynekologicko-porodnická klinika 1. LF UK a Fakultní nemocnice Bulovka, Praha

- 1 Kagabu, M. – Nagasawa, T. – Sato, C., et al.: Immunotherapy for uterine cervical cancer using checkpoint inhibitors: future directions. *Int J Mol Sci*, 2020, 21, s. 2335.
- 2 Peralta-Zaragoza, O. – Bermúdez-Morales, V. H. – Pérez-Plasencia, C., et al.: Targeted treatments for cervical cancer: a review. *Onco Targets Ther*, 2012, 5, s. 315–328.
- 3 Jazaeri, A. A. – Zsiros, E. – Amaria, R. N., et al.: Safety and efficacy of adoptive cell transfer using autologous tumor infiltrating lymphocytes (LN-145) for treatment of recurrent, metastatic, or persistent cervical carcinoma. *J Clin Oncol*, 2019, 37, suppl. 15, s. 2538.
- 4 Eskander, R. N. – Tewari, K. S.: Immunotherapy: an evolving paradigm in the treatment of advanced cervical cancer. *Clin Therapeutics*, 2015, 37, s. 20–38.
- 5 Enwere, E. K. – Kornaga, E. N. – Dean, M., et al.: Expression of PD-L1 and presence of CD8-positive T cells in pre-treatment specimens of locally advanced cervical cancer. *Mod Pathol*, 2017, 30, s. 577–586.
- 6 Browne, I. – Fennelly, D. W. – Crown, J., et al.: The efficacy and safety of pembrolizumab in advanced cervical cancer – A real world treatment study in an Irish healthcare setting. *J Clin Oncol*, 2020, 38, suppl. 15, DOI: 10.1200/JCO.2020.38.15\_suppl.e18007.
- 7 da Silva, D. M. – Enserro, D. M. – Mayadev, J. S., et al.: Immune

- activation in patients with locally advanced cervical cancer treated with ipilimumab following definitive chemoradiation (GOG-9929). *Clin Cancer Research*, 2021, 26, s. 5621–5630.
- 8 Naumann, R. W. – Oaknin, A. – Meyer, T., et al.: Efficacy and safety of nivolumab (Nivo) + ipilimumab (Ipi) in patients (pts) with recurrent/metastatic (R/M) cervical cancer: results from CheckMate 358. *Ann Oncol*, 2019, 30, suppl. 5, s. LBA62.
  - 9 Tewari, K. S. – Monk, B. J. – Vergote, I., et al.: VP4-2021: EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9: Interim analysis of phase III trial of cemiplimab vs. investigator's choice (IC) chemotherapy (chemo) in recurrent/metastatic (R/M) cervical carcinoma. *Ann Oncol*, 2021, 32, s. 940–941.
  - 10 O'Malley, D. M. – Oaknin, A. – Monk, B. J., et al.: Single-agent anti-PD-1 balstilimab or in combination with anti-CTLA-4 zalifrelimab for recurrent/metastatic (R/M) cervical cancer (CC): Preliminary results of two independent phase II trials. *Ann Oncol*, 2020, 31, suppl. 4, s. S1164–S1165.
  - 11 O'Malley, D. – Neffa, M. – Monk, B. J., et al.: 724MO Balstilimab (anti-PD-1) in combination with zalifrelimab (anti-CTLA-4): Final results from a phase II study in patients (pts) with recurrent/metastatic (R/M) cervical cancer (CC). *Ann Oncol*, 2021, 32, s. S727.
  - 12 Colombo, N. – Dubot, C. – Lorusso, D., et al.: LBA2 Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for persistent, recurrent, or metastatic cervical cancer: Randomized, double-blind, phase III KEYNOTE-826 study. *Ann Oncol*, 2021, 32, s. S1307–S1308.
  - 13 Song, Y. – Wang, C. – Li, X., et al.: 782P A retrospective study of toripalimab combined with concurrent chemoradiotherapy in patients with recurrent/advanced cervical cancer. *Ann Oncol*, 2021, 32, s. S755.
  - 14 Frenel, J. S. – Hervieu, A. – Borcoman, E., et al.: 775P Tremelimumab (T)+ durvalumab (D) combined with metronomic oral vinorelbine (MOV): Results of the recurrent cervical cancer (RCC) cohort of the MOVIE study. *Ann Oncol*, 2021, 32, s. S753.
  - 15 Youn, J. W. – Hur, S. Y. – Woo, J. W., et al.: Pembrolizumab plus GX-188E therapeutic DNA vaccine in patients with HPV-16-positive or HPV-18-positive advanced cervical cancer: Interim results of a single-arm, phase 2 trial. *Lancet Oncol*, 2020, 21, s. 1653–1660.
  - 16 Concin, N. – Matias-Guiu, X. – Vergote, I., et al.: ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma. *Int J Gynecol Cancer*, 2021, 31, s. 12–39.
  - 17 Humber, C. E. – Tierney, J. F. – Symonds, R. P., et al.: Chemotherapy for advanced, recurrent or metastatic endometrial cancer: A systematic review of Cochrane Collaboration. *Ann Oncol*, 2007, 18, s. 409–420.
  - 18 Fleming, G. F.: Second-line therapy for endometrial cancer: The need for better options. *J Clin Oncol*, 2015, 33, s. 3535–3540.
  - 19 Levine, D.: The Cancer Genome Atlas Research Network. Integrated genomic characterization of endometrial carcinoma. *Nature*, 2013, 0497, s. 67–73.
  - 20 Marcus, L. – Lemery, S. J. – Keegan, P., et al.: FDA Approval Summary: Pembrolizumab for the treatment of microsatellite instability-high solid tumors. *Clin Cancer Res*, 2019, 25, s. 3753–3758.
  - 21 FDA Grants Regular Approval to Pembrolizumab and Lenvatinib for Advanced Endometrial Carcinoma. Dostupné z: <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-regular-approval-pembrolizumab-and-lenvatinib-advanced-endometrial-carcinoma/>, vyhledáno 1. 12. 2021.
  - 22 Merck. European Commission Approves KEYTRUDA® (Pembrolizumab) Plus LENVIMA® (Lenvatinib) for Patients With Certain Types of Endometrial Carcinoma. Dostupné z: <https://www.merck.com/news/european-commissionapproves-keytruda-pembrolizumab-plus-lenvima-lenvatinib-for-patients-with-certain-types-of-endometrial-carcinoma/>, vyhledáno 1. 12. 2021.
  - 23 ESMO. EMA Recommends Granting a Conditional Marketing Authorisation for Dostarlimab. Dostupné z: <https://www.esmo.org/oncology-news/emarecommends-granting-a-conditional-marketing-authorisation-for-dostarlimab>, vyhledáno 1. 12. 2021.
  - 24 Marabelle, A. – Le, D. T. – Ascierto, P. A., et al.: Efficacy of pembrolizumab in patients with non colorectal high microsatellite instability/mismatch repair-deficient cancer: Results from the phase II KEYNOTE-158 study. *J Clin Oncol*, 2020, 38, s. 1–10.
  - 25 Le, D. T. – Durham, J. N. – Smith, K. N., et al.: Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. *Science*, 2017, 357, s. 409–413.
  - 26 Fader, A. N. – Diaz, L. A. – Armstrong, D. K., et al.: Preliminary results of a phase II study: PD-1 blockade in mismatch repair-deficient, recurrent or persistent endometrial cancer. *Gynecol Oncol*, 2016, 141, s. 206–207.
  - 27 Roque, D. M. – Bellone, S. – Siegel, E. R., et al.: A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH1 methylated characteristics (NCT02899793). *JCO*, 2021, 39, s. 5523–5523.
  - 28 Ott, P. A. – Bang, Y.-J. – Berton-Rigaud, D., et al.: Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1-positive endometrial cancer: Results from the KEYNOTE-028 study. *J Clin Oncol*, 2017, 35, s. 2535–2541.
  - 29 Makker, V. – Taylor, M. H. – Aghajanian, C., et al.: Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer. *J Clin Oncol*, 2020, 38, s. 2981–2992.
  - 30 Makker, V. – Colombo, N. – Casado Herráez, A., et al.: Society of Gynecologic Oncology 2021 Virtual Annual Meeting on Women's Cancer. A Multicenter, Open-Label, Randomized Phase 3 Study to Compare the Efficacy and Safety of Lenvatinib in Combination With Pembrolizumab vs. Treatment of Physician's Choice in Patients With Advanced Endometrial Cancer: Study 309/KEYNOTE-775. *Int J Gynecol Cancer*, 2021, 31, s. A4–A5.
  - 31 Tamura, K. – Hasegawa, K. – Katsumata, N., et al.: Efficacy and safety of nivolumab in Japanese patients with uterine cervical cancer, uterine corpus cancer, or soft tissue sarcoma: multicenter, open-label phase 2 trial. *Cancer Sci*, 2019, 110, s. 2894–904.
  - 32 Lheureux, S. – Matei, D. – Konstantinopoulos, P. A., et al.: A randomized phase II study of cabozantinib and nivolumab versus nivolumab in recurrent endometrial cancer. *JCO*, 2020, 38, suppl. 15, s. 6010–6010.
  - 33 Oaknin, A. – Duska, L. R. – Sullivan, R. J., et al.: Preliminary safety, efficacy, and pharmacokinetic/pharmacodynamic characterization from GARNET, a phase I/II clinical trial of the anti-PD-1 monoclonal antibody, TSR-042, in patients with recurrent or advanced MSI-H and MSS endometrial cancer. *Gynecologic Oncology*, 2019, 154, s. 17.

## Prevence recidivujících infekcí močových cest bakteriálními lyzáty

doc. MUDr. Peter Koliba, CSc. Gynekologická ambulance Gynartis, s. r. o., Ostrava

- 1 Stamm, W. E. – Norrby, S. R.: Urinary tract infections: disease panorama and challenges. *J Infect Dis*, 2001, 183, suppl. 1, s. S1–S4.
- 2 EAU Guidelines. Edn. presented at the EAU Annual Congress Amsterdam, the Netherlands 2022. ISBN 978-94-92671-16-5.
- 3 Brodie, A. – El-Taji, O. – Jour, I., et al.: A retrospective study of immunotherapy treatment with Uro-Vaxom (OM-89\*) for prophylaxis of recurrent urinary tract infections. *Curr Urol*, 2020, 14, s. 130–134.
- 4 Taha Neto, K. A. – Nogueira Castilho, L. – Reis, L. O.: Oral vaccine (OM-89) in the recurrent urinary tract infection prophylaxis: a realistic systematic review with meta-analysis. *Actas Urol Esp*, 2016, 40, s. 203–208.
- 5 Tammen, H.: Immunobiotherapy with Uro Vaxom in recurrent urinary tract infection. *Br J Urol*, 1990, 65, s. 6–9.
- 6 Schulman, C. C. – Corbusier, A. – Michiels, H., et al.: Oral immunotherapy of recurrent urinary tract infections: a double-blind placebo-controlled multicenter study. *J Urol*, 1993, 150, s. 917–922.
- 7 Huber, M. – Krauter, K. – Winkelmann, G., et al.: Immunostimulation by bacterial components: II. Efficacy studies and meta-analysis of the bacterial extract OM-89. *Int J Immunopharmacol*, 2000, 22, s. 1103–1111.
- 8 Magasi, P. – Pánovics, J. – Illés, A., et al.: UroVaxom and the management of recurrent urinary tract infection in adults: a randomized multicenter double-blind trial. *Eur Urol*, 1994, 26, s. 137–140.
- 9 Bauer, H. W. – Alloussi, S. – Egger, G.: A long-term, multicenter, double-blind study of an Escherichia coli extract (OM-89) in female patients with recurrent urinary tract infections. *Eur Urol*, 2005, 47, s. 542–548.
- 10 Foxman, B.: Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. *Am J Med*, 2002, 113, suppl. 1A, s. S5–S13S.
- 11 Bystron, J.: Využití bakteriálních lyzátů v klinické praxi. *Medicina pro praxi*, 2012, 9, s. 336–341.
- 12 Ryšánková, M.: Lčba a prevence recidivujících infekcí močových cest. *Urologie pro praxi*, 2019, 20, s. 54–57.

## První klinické zkušenosti s pivmecilinamem v terapii nekomplikovaných infekcí dolních močových cest – kazuistiky

prof. MUDr. Jan Krhut, Ph.D. Urologická klinika FN Ostrava, Katedra chirurgických oborů LF OU, Ostrava

- 1 Colgan, R. – Williams, M.: Diagnosis and treatment of acute uncomplicated cystitis. *Am Fam Physician*, 2011, 84, s. 771–776.
- 2 European Association of Urology. EAU guidelines on urological infections, 2021. Dostupné z: <https://uroweb.org/guideline/urological-infections>, vyhledáno 1. 4. 2022.
- 3 Foxman, B.: Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden. *Infect Dis Clin North Am*, 2014, 28, s. 1–13.
- 4 McLellan, L. K. – Hunstad, D. A.: Urinary tract infection: pathogenesis and outlook. *Trends Mol Med*, 2016, 22, s. 946–957.
- 5 Dostupné z: [www.sukl.cz/pivnorm-spc](http://www.sukl.cz/pivnorm-spc), vyhledáno 25. 3. 2022.
- 6 Bresky, B.: Controlled randomized study comparing amoxicillin and pivmecillinam in adult out-patients presenting with symptoms of acute urinary tract infection. *J Antimicrob Chemother*, 1977, 3, s. 121–127.
- 7 Petersen, S. – Brendstrup, L. – Petersen, K. E.: Short-term treatment of acute urinary tract infection in girls. *Scand J Infect Dis*, 1991, 23, s. 213–220.
- 8 Brumfitt, W. – Franklin, I. – Hamilton-Miller, J.: Comparison of pivmecillinam and cephadrine in bacteriuria in pregnancy and in acute urinary tract infection. *Scand J Infect Dis*, 1979, 11, s. 275–279.
- 9 Montelin, H. – Forsman, K. J. – Tängdén, T.: Retrospective evaluation of nitrofurantoin and pivmecillinam for the treatment of lower urinary tract infections in men. *PLoS One*, 2019, 14, s. e0211098.
- 10 Bollestad, M. – Grude, N. – Solhaug, S., et al.: the Norwegian ESBL UTI study group: Clinical and bacteriological efficacy of pivmecillinam treatment for uncomplicated urinary tract infections caused by ESBL-producing Escherichia coli: a prospective, multicentre, observational cohort study. *J Antimicrob Chemother*, 2018, 73, s. 2503–2509.
- 11 Nicolle, L. E.: Pivmecillinam in the treatment of urinary tract infections. *J Antimicrob Chemother*, 2000, 46, suppl. 1, s. 35–39.
- 12 Pinart, M. – Kranz, J. – Jensen, K., et al.: Optimal dosage and duration of pivmecillinam treatment for uncomplicated lower urinary tract infections: a systematic review and meta-analysis. *Int J Infect Dis*, 2017, 58, s. 96–109.
- 13 Haugom, L. E. A. – Ruths, S. – Emberland, K. E., et al.: Consultations and antibiotic treatment for urinary tract infections in Norwegian primary care 2006–2015, a registry-based study. *BMC Fam Pract*, 2021, 22, s. 127.
- 14 Bader, M. S. – Loeb, M. – Leto, D., et al.: Treatment of urinary tract infections in the era of antimicrobial resistance and new antimicrobial agents. *Postgrad Med*, 2020, 132, s. 234–250.
- 15 Dostupné z: [http://www.szu.cz/uploads/documents/CeM/NRLs/atb/PSMR/mocova\\_studie/2021/PSMR\\_2021\\_EC.pdf](http://www.szu.cz/uploads/documents/CeM/NRLs/atb/PSMR/mocova_studie/2021/PSMR_2021_EC.pdf), vyhledáno 25. 3. 2022.
- 16 Jansáker, F. – Fridomdt-Møller, N. – Benfield, T. L., et al.: Mecillinam for the treatment of acute pyelonephritis and bacteremia caused by Enterobacteriaceae: a literature review. *Infect Drug Resist*, 2018, 11, s. 761–771.

# Hyperaktivní močový měchýř – farmakologické možnosti léčby

MUDr. Marek Gojdič, Ph.D. UROGYN MEDICO, privátní urologická klinika, Urologické oddělení Fakultní nemocnice Bulovka, Praha

MUDr. Miroslava Ryšánková privátní urologická ambulance Náchod

- Haylen, B. T. – de Ridder, D. – Freeman, R. M., et al.: An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. *Int Urogynecol J*, 2010, 21, s. 5–26.
- Topinková, E.: Farmakoterapie urgentní inkontinence a hyperaktivního měchýře u seniorů. *Urol Praxi*, 2017, 18, s. 148–153.
- Abrams, P. – Cardozo, L. – Fall, M., et al.: for the Standardisation Sub-committee of the International Continence Society: The standardisation of terminology of lower urinary tract function: Report from the Standardisation Sub-committee of the International Continence Society. *Neurourology and Urodyn*, 2002, 21, s. 167–178.
- Romžová, M. – Hurtová, M. – Pacovský, J., et al.: Inkontinence moče ve stáří. *Urolog Praxi*, 2010, 11, s. 119–123.
- Verner, P.: Porovnání účinnosti a vedlejších účinků anticholinergik při léčbě OAB. *Urolog Praxi*, 2010, 11, s. 241–246.
- Romžová, M. – Hurtová, M. – Pacovský, J., et al.: Farmakoterapie a její úskalí v léčbě urgentní inkontinence a hyperaktivního močového měchýře. *Urolog Praxi*, 2011, 12, s. 229–233.
- Chapple, C. – Khullar, V. – Gabriel, Z., et al.: The effects of antimuscarinic treatments in over active bladder: a systematic review and meta-analysis. *Eur Urol*, 2005, 48, s. 5–26.
- Horčíčka, L. – Zchoval, R. – Vlková, J., et al.: *Diagnostika a léčba močové inkontinence u žen*. Novelizace 2017, Centrum doporučených postupů pro praktické lékaře, SVL ČLS JEP, 2017.
- Poršová, M. – Kolombo, I. – Porš, J., et al.: Urgentní mikce a inkontinence a možnosti jejich farmakologické léčby. *Urolog Praxi*, 2008, 9, s. 302–306.
- Krhut, J.: Inkontinence moče u geriatrických pacientů. *Česká geriatrická revue*, 2003, 3, s. 40–47.
- Krhut, J.: *Hyperaktivní močový měchýř*. Jessenius Maxdorf, Praha, 2007, s. 149.
- Bergmans, L. – Hendrick, H. – de Brie, R., et al.: Conservative treatment of urge urinary incontinence in women: a systematic review of randomized clinical trials. *BJU Int*, 2000, 85, s. 254–263.
- Andersson, K. E.: Antimuscarinic mechanism and the overactive detrusor: an update. *Eur Urol*, 2011, 59, s. 377–386.
- Topinková, E.: Úskalí farmakologické léčby urgentní inkontinence a hyperaktivního měchýře ve stáří. *Lékařské listy ZN*, 2009, 18, suppl., s. 21–24.
- Topinková, E.: Farmakoterapie hyperaktivního močového měchýře ve stáří. *Medicina pro praxi*, 2010, 11, suppl. 1, s. 36–44.
- Risacher, S. L. – McDonald, B. C. – Tallman, E. F., et al.: Association between anticholinergic medication use and cognition, brain metabolism, and brain atrophy in cognitively normal older adults. *JAMA Neurol*, 2016, 73, s. 721–732.
- Topinková, E.: Nežádoucí účinky antimuskarínik na centrální nervový systém. *Urol Listy*, 2012, 10, s. 69–74.
- Drlik, P.: Nykturie – současné možnosti terapie. *Urolog Praxi*, 2010, 11, s. 176–179.
- Kuo, H. C. – Liao, C. H. – Chung, S. D.: Adverse events of intravesical botulinum toxin A injections for idiopathic detrusor overactivity: risk factors and influence on treatment outcome. *Eur Urol*, 2010, 58, s. 919–926.
- Saks, E. K. – Lily, A. A.: Pharmacologic management of overactive bladder. *Female Patient*, 2010, 11, s. 24–29.
- Krhut, J.: Současný pohled na diagnostiku inkontinence moči a léčbu. *Postgraduální Med*, 2008, 3, s. 32–39.
- Burešová, E. – Vidlář, A. – Študent, V.: OAB a inkontinence moči. *Med Praxi*, 2012, 9, s. 179–182.
- Schurich, B. – Stohrer, M. – Kramer, G., et al.: Botulinum A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. *J Urol*, 2000, 164, s. 692–697.

## Komplexní léčba gynekologických zánětů

MUDr. Jana Kadlecová Gynekologicko-porodnická klinika LF MU a FN Brno

- Líbalová, Z. – Čepický, P.: Vulvovaginitis. *Moderní gynekologie a porodnictví*, 2008, suppl. 17, s. 139–145.
- Mašata, J. – Jedličková, A. – Poislová, M., et al.: Současné možnosti diagnostiky vulvovaginálních infekcí. *Čes Gynek*, 2010, 2, s. 111–117.
- Mašata J. – Posilová, M. – Jedličková, A., et al.: Modifikování klasifikace mikroskopického hodnocení poševních infekcí. *Čes Gynek*, 2010, 3, s. 1991–1208.
- Bagnall, P. – Rizzolo, D.: Bacterial vaginosis: A practical review. *JAAPA*, 2017, 30, s. 15–21.
- Horowitz, B. – Marđh, P. – Nagy, E., et al.: Vaginal lactobacillosis. *Am J Obstet Gynecol*, 1994, 170, s. 857–861.
- Maamer, M. – Arousseau, M.: Concentration of benzydamine in vaginal mucosa following local application: an experimental and clinical study. *Int J Tissue React*, 1987, 9, s. 135–145.
- Fanaki, N. H. – el Nakeeb, M. A.: Antimicrobial activity of benzydamine, a non-steroid anti-inflammatory agent. *J Chemother*, 1992, 4, s. 347–352.
- Šuška et al.: Použití benzydaminu (ROSALGIN) a nifuratelu s nystatinom (MACMIRROR COMPLEX) v léčbě akutní vulvovaginitidy. *Slav. Gynek Porod*, 2009, 16, s. 118–125.

## Současné možnosti terapie vulvovaginální kandidózy

doc. MUDr. Petr Hamal, Ph.D. | MDDr. Lucie Svobodová, Ph.D. Ústav mikrobiologie LF UP a FN Olomouc

- Farr, A. – Effendy, I. – Tirri, B. F., et al.: Vulvovaginal Candidosis (Excluding Mucocutaneous Candidosis): Guideline of the German (DGGG), Austrian (OEGGG) and Swiss (SöGG) Society of Gynecology and Obstetrics (S2k-Level), AWMF Registry Number 015/072, September 2020. *Geburtshilfe Frauenheilkd*, 2021, 81, s. 398–421.
  - Farr, A. – Effendy, I. – Frey, B., et al.: Guideline: Vulvovaginal candidosis (AWMF 015/072, level S2k). *Mycoses*, 2021, 64, s. 583–602.
  - Matheson, A. – Mazza, D.: Recurrent vulvovaginal candidiasis: A review of guideline recommendations. *Aust N Z J Obstet Gynaecol*, 2017, 57, s. 139–145.
  - Lines, A. – Vardi-Flynn, I. – Searle, C.: Recurrent vulvovaginal candidiasis. *BMJ*, 2020, 369, s. 1995.
  - Hamal, P. – Svobodová, L.: Léčba mykotických infekcí v gynekologii. *Acta Medica*, 2021, 10, s. 57–59.
  - Hamal, P. – Svobodová, L.: Mykózy a antimykotika. *Interní Med*, 2011, 13, s. 445–449.
- Další literatura u autora

## Farmakologická léčba mimoděložního těhotenství

MUDr. Borek Sehnal, Ph.D. Gynekologicko-porodnická klinika, Fakultní nemocnice Bulovka a 1. LF UK, Praha, Nemocnice Neratovice

MUDr. Peter Koliba Gynekologicko-porodnická klinika, Fakultní nemocnice Bulovka a 1. LF UK, Praha

- Hsu, J. Y. – Chen, L. – Gumer, A. R., et al.: Disparities in the management of ectopic pregnancy. *Am J Obstet Gynecol*, 2017, 217, s. 49.e1–49.e10.
- Tay, J. I. – Moore, J. – Walker, J. J.: Ectopic pregnancy. *BMJ*, 2000, 320, s. 916–919.
- Zdeňková, A. – Fanta, M. – Calda, P.: Metotrexát v léčbě ektoické gravidity. *Actual Gyn*, 2015, 7, s. 27–32.
- Cordeiro, D. E. F. – Alves, J. A. G. – Araujo Jr. E., et al.: Ectopic pregnancies: a retrospective cohort analysis in a tertiary reference center in the Northeast Region of Brazil. *Čes Gynek*, 2018, 83, s. 434–439.
- Elson, C. J. – Salim, R. – Potdar, N., et al.: Diagnosis and management of ectopic pregnancy. On behalf of the Royal College of Obstetricians and Gynaecologists. *BJOG*, 2016, 123, s. e15–e55.
- Mavrellos, D. – Nicks, H. – Jamil, A., et al.: Efficacy and safety of a clinical protocol for expectant management of selected women diagnosed with a tubal ectopic pregnancy. *Ultrasound Obstet Gynecol*, 2013, 42, s. 102–107.
- van Mello, N. M. – Mol, F. – Verhoeve, H. R., et al.: Methotrexate or expectant management in women with an ectopic pregnancy or pregnancy of unknown location and low serum hCG concentrations? A randomized comparison. *Hum Reprod*, 2012, 28, s. 60–67.
- Shalev, E. – Peleg, D. – Tsbari, A., et al.: Spontaneous resolution of ectopic tubal pregnancy: natural history. *Fertil Steril*, 1995, 63, s. 15–19.
- Tanaka, T. – Hayashi, H. – Kutsuzawa, T., et al.: Treatment of interstitial ectopic pregnancy with methotrexate: report of a successful case. *Fertil Steril*, 1982, 37, s. 851–852.
- Hajenius, P. J. – Mol, F. – Mol, B. W., et al.: Interventions for tubal ectopic pregnancy. *Cochrane Database Syst Rev*, 2007, 2007, s. CD000324.
- Barnhart, K. T. – Gosman, G. – Ashby, R., et al.: The medical management of ectopic pregnancy: a meta-analysis comparing „single dose“ and „multidose“ regimens. *Obstet Gynecol*, 2003, 101, s. 778–784.
- Menon, S. – Colins, J. – Barnhart, K. T.: Establishing a human chorionic gonadotropin cutoff to guide methotrexate treatment of ectopic pregnancy: a systematic review. *Fertil Steril*, 2007, 87, s. 481–484.
- Soliman, K. B. – Saleh, N. M. – Omran, A. A.: Safety and efficacy of systemic methotrexate in the treatment of unruptured tubal pregnancy. *Saudi Med J*, 2016, 27, s. 1005–1010.
- Sagiv, R. – Debby, A. – Feit, H., et al.: The optimal cutoff serum level of human chorionic gonadotropin for efficacy of methotrexate treatment in women with extrauterine pregnancy. *Int J Gynaecol Obstet*, 2012, 116, s. 101–104.
- Racková, J. – Driák, D. – Neumannová, H., et al.: Použití metotrexátu u ektoické gravidity a těhotenství neznámé lokalizace. *Čes Gynek*, 2016, 81, s. 141–146.
- Hung, T. H. – Chau, W. Y. – Tsieh, J. J., et al.: Prognostic factors for an unsatisfactory primary methotrexate treatment of cervical pregnancy: a quantitative review. *Hum Reprod*, 1998, 13, s. 2636–2642.

## Pilotní projekt časného zachytu tyreopatií v graviditě

MUDr. Marcela Koudelková | Mgr. Renata Chloupková | Mgr. Jan Kouřil | Mgr. Ondřej Ngo | PhDr. Karel Hejduk | prof. RNDr. Ladislav Dušek, Ph.D. | RNDr. Ondřej Májek, Ph.D. Národní screeningové centrum, Ústav zdravotnických informací a statistiky ČR, Praha, Institut biostatistiky a analýz, LF MUNI, Brno  
doc. MUDr. Jan Jiskra, Ph.D. | doc. MUDr. Zdenka Límanová, CSc. III. interní klinika 1. LF UK a VFN, Praha  
doc. Ing. Drahomíra Springer, Ph.D. Ústav lékařské biochemie a laboratorní diagnostiky 1. LF UK a VFN, Praha

- Alexander, E. K. – Pearce, E. N. – Brent, G. A., et al.: 2017 Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and the postpartum. *Thyroid*, 2017, 27, s. 315–389.
- DeGroot, L. – Abalovich, M. – Alexander, E. K., et al.: Management of thyroid dysfunction during pregnancy and postpartum: An Endocrine Society practice guideline. *J Clin Endocrinol Metab*, 2012, 97, s. 2543–2565.
- Horacek, J. – Spitalnikova, S. – Dlabalova, B., et al.: Universal screening detects two-times more thyroid disorders in early pregnancy than targeted high-risk case finding. *Eur J Endocrinol*, 2010, 163, s. 645–650.
- Horáček, J. – Jiskra, J. – Límanová, Z., et al.: Doporučení pro diagnostiku a léčbu onemocnění štítné žlázy v těhotenství a pro ženy s poruchou fertility. *Vnitř Lék*, 2013, 59, s. 909–931.
- Jiskra, J. – Bartáková, J. – Holinka, Š., et al.: Low prevalence of clinically high-risk women and pathological thyroid ultrasound among pregnant women positive in universal screening for thyroid disorders. *Exp Clin Endocrinol Diabetes*, 2011, 119, s. 530–535.
- Jiskra, J. – Bartáková, J. – Holinka, Š., et al.: Low concordance between positive antibodies to thyroperoxidase and thyroid ultrasound autoimmune pattern in pregnant women. *Endocr J*, 2011, 58, s. 849–859.
- Springer, D. – Zima, T. – Límanová, Z.: Reference intervals in evaluation of maternal thyroid function during the first trimester of pregnancy. *Eur J Endocrinol*, 2009, 160, s. 791–797.
- Stagnaro-Green, A. – Abalovich, M. – Alexander, E., et al.: Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and postpartum. *Thyroid*, 2011, 21, s. 1–45.

## Očkování v těhotenství

doc. MUDr. Michal Koucký, Ph.D. Gynekologicko-porodnická klinika 1. LF UK a VFN, Praha

- Englund, J. A.: The influence of maternal immunization on infant immune responses. *J Comp Pathol*, 2007, 137, suppl. 1, s. S16–S19.
- Paterson, P. – Meurice, F. – Stanberry, L. R., et al.: Vaccine hesitancy and healthcare providers. *Vaccine*, 2016, 34, s. 6700–6706.
- Gonik, B. – Fasano, N. – Foster, S.: The obstetrician-gynecologist's role in adult immunization. *Am J Obstet Gynecol*, 2002, 187, s. 984–988.
- ACOG Committee Opinion No. 772: Immunization Implementation Strategies for Obstetrician-Gynecologists. *Obstet Gynecol*, 2019, 133, s. e254–e259.
- DeSesso, J. M. – Williams, A. L. – Ahuja, A., et al.: The placenta, transfer of immunoglobulins, and safety assessment of biopharmaceuticals in pregnancy. *Crit Rev Toxicol*, 2012, 42, s. 185–210.
- United States Centers for Disease Control. ACIP: Guidance for Vaccine Recommendations in Pregnant and Breastfeeding Women, 2016. Dostupné z: <https://www.cdc.gov/vaccines/pregnancy/hcp-toolkit/guidelines.html>, vyhledáno 1. 5. 2019.
- Keller-Stanislawski, B. – Englund, J. A. – Kang, G., et al.: Safety of immunization during pregnancy: a review of the evidence of selected inactivated and live attenuated vaccines. *Vaccine*, 2014, 32, s. 7057–7064.
- Dostupné z: [www.cdc.gov/vaccines/schedules/hcp/adult.html](http://www.cdc.gov/vaccines/schedules/hcp/adult.html), vyhledáno 20. 2. 2015.
- Dostupné z: [www.cdc.gov/vaccines/schedules/hcp/adult.html](http://www.cdc.gov/vaccines/schedules/hcp/adult.html), vyhledáno 20. 2. 2015.
- Keller-Stanislawski, B. – Englund, J. A. – Kang, G., et al.: Safety of immunization during pregnancy: a review of the evidence of selected inactivated and live attenuated vaccines. *Vaccine*, 2014, 32, s. 7057–7064.
- Pickering, L. K. – Baker, C. J. – Freed, G. L., et al.: Infectious Diseases Society of America: Immunization programs for infants, children, adolescents, and adults: clinical practice guidelines by the Infectious Diseases Society of America. *Clin Infect Dis*, 2009, 49, s. 817–840.
- Liang, J. L. – Tiwari, T. – Moro, P., et al.: Prevention of pertussis, tetanus, and diphtheria with vaccines in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP). *Recommendations and Reports*, 2018, 67, s. 1–44.
- Grohskopf, L. A. – Alyanak, E. – Ferdinands, J. M., et al.: Prevention and control of seasonal influenza with vaccines: recommendations of the advisory committee on immunization practices, United States, 2021–22 influenza season. *Recommendations and Reports*, 2021, 70, s. 1–28.
- Munoz, F. M.: Can we protect pregnant women and young infants from COVID-19 through maternal immunization? *JAMA Pediatr*, 2021, 175, s. 561–562.
- Wainstock, T. – Yoles, I. – Sergienko, R., et al.: Prenatal maternal COVID-19 vaccination and pregnancy outcomes. *Vaccine*, 2021, 39, s. 6037–6040.
- Stafford, I. A. – Parchem, J. G. – Sibai, B. M.: The coronavirus disease 2019 vaccine in pregnancy: risks, benefits, and recommendations. *Am J Obstet Gynecol*, 2021, 224, s. 484–495.
- Shimabukuro, T. T. – Kim, S. Y. – Myers, T. R., et al.: CDC v-safe COVID-19 Pregnancy Registry Team: Preliminary findings of mRNA covid-19 vaccine safety in pregnant persons. *N Engl J Med*, 2021, 384, s. 2273–2282.
- Chaithongwongwatthana, S. – Yamasmith, W. – Limpongsanurak, S., et al.: Pneumococcal vaccination during pregnancy for preventing infant infection. *Cochrane Database of Systematic Reviews*, 2015, CD004903, DOI: 10.1002/14651858.CD004903.pub4.
- Chu, H. Y. – Englund, J. A.: Maternal immunization. *Birth Defects Res*, 2017, 109, s. 379–386.
- Mbaeyi, S. A. – Bozio, C. H. – Duffy, J., et al.: Meningococcal vaccination: recommendations of the Advisory Committee on Immunization Practices, United States, 2020. *MMWR Recomm Rep*, 2020, 69, s. 1–41.
- American College of Obstetricians and Gynecologists: ACOG Practice Bulletin No. 86: Viral hepatitis in pregnancy. *Obstet Gynecol*, 2007, 110, s. 941–956.
- Staples, J. E. – Gershman, M. – Fischer, M.: Centers for Disease Control and Prevention (CDC): Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep*, 2010, 59, s. 1–27.
- Sulaiman, K. – Sarwari, A. R.: Culture-confirmed typhoid fever and pregnancy. *Int J Infect Dis*, 2007, 11, s. 337–341.
- Sudarshan, M. K. – Giri, M. S. – Mahendra, B. J., et al.: Assessing the safety of post-exposure rabies immunization in pregnancy. *Hum Vaccin*, 2007, 3, s. 87–89.
- Centers for Disease Control and Prevention (CDC): FDA approval of an extended period for administering Vari ZIG for post exposure prophylaxis of varicella. *MMWR Morb Mortal Wkly Rep*, 2012, 61, s. 212.
- Dostupné z: [www.szu.cz/uploads/Epidemiologie/Ockovani/ockovaci\\_kalendar\\_pro\\_deti\\_2021\\_01\\_01.pdf](http://www.szu.cz/uploads/Epidemiologie/Ockovani/ockovaci_kalendar_pro_deti_2021_01_01.pdf), vyhledáno 3. 5. 2022.

## Covid-19 a těhotenství

MUDr. Simona Mlezivová | prof. MUDr. Michal Zikán, Ph.D. Gynekologicko-porodnická klinika 1. LF UK a Fakultní nemocnice Bulovka, Praha

- Coronavirus Pandemic (COVID-19) – Our World in Data. Dostupné z: <https://ourworldindata.org/coronavirus>, vyhledáno 21. 2. 2022.
- Rasmussen, S. A. – Jamieson, D. J.: Coronavirus disease 2019 and pregnancy is déjà vu all over again. *BJOG*, 2022, 129, s. 188–191.
- Jamieson, D. J. – Rasmussen, S. A.: An update on COVID-19 and pregnancy. *Ame J Obstet Gynecol*, 2022, 226, s. 177–186.
- Allotey, J. – Stallings, E. – Bonet, M., et al.: Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: Living systematic review and meta-analysis. *BMJ*, 2020, 370.
- Bellos, I. – Pandita, A. – Panza, R.: Maternal and perinatal outcomes in pregnant women infected by SARS-CoV-2: A meta-analysis. *Eur J Obstet Gynecol Reprod Biol*, 2021, 256, s. 194–204.
- Berghella, V. L. – Hughes, B.: COVID-19: Pregnancy issues and antenatal care. 2020, s. 1–37. Dostupné z: <https://www.uptodate.com/contents/covid-19-overview-of-pregnancy-issues>, vyhledáno 13. 4. 2022.
- DeSisto, C. L. – Wallace, B. – Simeone, R. M., et al.: Risk for stillbirth among women with and without COVID-19 at delivery hospitalization – United States, March 2020–September 2021. *MMWR Morb Mortal Wkly Rep*, 2021, 70, s. 1640–1645.
- Metz, T. D. – Clifton, R. G. – Hughes, B. L., et al.: Disease severity and perinatal outcomes of pregnant patients with coronavirus disease 2019 (COVID-19). *Obstet Gynecol*, 2021, 137, s. 571–580.
- Papageorgiou, A. T. – Deruelle, P. – Gunier, R. B., et al.: Preeclampsia and COVID-19: results from the INTERCOVID prospective longitudinal study. *Am J Obstet Gynecol*, 2021, 225, s. 289.e1–289.e17.
- Villar, J. – Ariff, S. – Gunier, R. B., et al.: Maternal and neonatal morbidity and mortality among pregnant women with and without COVID-19 infection: The INTERCOVID Multinational Cohort Study. *JAMA Pediatr*, 2021, 175, s. 817–826.
- Kelly, J. C. – Raghuraman, N. – Carter, E. B., et al.: Preprocedural asymptomatic coronavirus disease 2019 cases in obstetrical and surgical units. *Am J Obstet Gynecol*, 2021, 224, s. 114–116.
- Yang, J. – D'Souza, R. – Kharrat, A., et al.: COVID-19 pandemic and population-level pregnancy and neonatal outcomes in general population: A living systematic review and meta-analysis (Update#2: November 20, 2021). *Acta Obstetrica et Gynecologica Scandinavica*, 2022, 101, s. 273–292.
- Mendez-Dominguez, N. – Santos-Zaldívar, K. – Gomez-Carro, S., et al.: Maternal mortality during the COVID-19 pandemic in Mexico: a preliminary analysis during the first year. *BMC Public Health*, 2021, 21, 1297, <https://doi.org/10.1186/s12889-021-11325-3>.
- Cosma, S. – Carosso, A. R. – Cusato, J., et al.: Coronavirus disease 2019 and first-trimester spontaneous abortion: a case-control study of 225 pregnant patients. *Am J Obstet Gynecol*, 2021, 224, s. 391.e1.
- Chen, H. – Guo, J. – Wang, C., et al.: Clinical characteristics and intra-uterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. *Lancet*, 2020, 395, s. 809–815.
- Dong, L. – Tian, J. – He, S., et al.: Possible vertical transmission of SARS-CoV-2 from an infected mother to her newborn. *JAMA*, 2020, 323, s. 1846–1848.
- Kimberlin, D. W. – Stagno, S.: Can SARS-CoV-2 infection be acquired in utero? More definitive evidence is needed. *JAMA*, 2020, 323, s. 1788–1789.
- Ross-Davie, M., et al.: Guidance for antenatal and postnatal services in the evolving coronavirus (COVID-19) pandemic. *Royal College of Obstetricians and Gynaecologists*. Dostupné z: <https://www.rcm.org.uk/media/3837/guidance-for-antenatal-and-postnatal-services-in-the-evolving-coronavirus-pandemic-rcm-and-rcog.pdf>, vyhledáno 14. 4. 2022.
- Omar, M. – Youssef, M. R. – Trinh, L. N., et al.: Excess of cesarean births in pregnant women with COVID-19: A meta-analysis. *Birth*, 2022, <https://doi.org/10.1111/birt.12609>, publikováno před tiskem.
- COVID-19 and Special Populations. Dynamed. Dostupné z: <https://www.dynamed.com/condition/covid-19-and-special-populations>, vyhledáno 14. 4. 2022.
- Servante, J. – Swallow, G. – Thornton, J. G., et al.: Haemostatic and thrombo-embolic complications in pregnant women with COVID-19: a systematic review and critical analysis. *BMC Pregnancy Childbirth*, 2021, 21, 108.
- Doporučený postup České společnosti pro trombózu a hemostázu

ČLS JEP: Antitrombotická profylaxe u nemocných s covid-19. Dostupné z: <https://www.cls.cz/media/document/55d693037038dc2ec59ad0b553fa44d6.pdf>, vyhledáno 14. 4. 2022.

23 Blakeway, H. – Prasad, S. – Kalafat, E., et al.: COVID-19 vaccination

during pregnancy: coverage and safety. *Am J Obstet Gynecol*, 2022, 226, s. 236.e1–236.e14.

24 Stock, S. J. – Carruthers, J. – Calvert, C., et al.: SARS-CoV-2 infection and COVID-19 vaccination rates in pregnant women in Scotland. *Nat*

*Med*, 2022, 28, s. 504–512.

25 Dostupné z: <https://www.acog.org/-/media/project/acog/acogorg/files/pdfs/clinical-guidance/practice-advisory/covid-19-algorithm.pdf>, vyhledáno 19. 4. 2022.

## Význam moderních přístupů k suplementaci železa pro zdraví ženy

doc. MUDr. Tomáš Fait, Ph.D. Gynekologicko-porodnická klinika 2. LF UK a FN v Motole, Praha

- 1 Vyoral, D. – Petrák, J.: Metabolismus železa a jeho regulace. *Vnitřní Léč*, 2012, 58, suppl. 2, s. 25115–25126.
- 2 Sox, H. C. – Berwick, D. M. – Berg, A. O., et al.: Routine iron supplementation during pregnancy. Review article. *JAMA*, 1993, 270, s. 2848–2854.
- 3 Vrábliková, H. – Koucký, M.: Anémie v gynekologii a perinatologii. *Prakt Gyn*, 2015, 19, s. 230–233.
- 4 Galan, P. – Yoon, H. C. – Preziosi, P., et al.: Determining factors in the iron status of adult women in the SUVIMAX study. *Eur J Clin Nutrition*, 1998, 52, s. 383–388.
- 5 Provan, D.: Mechanism and management of iron deficiency anaemia. *Br J Haematol*, 1999, 105, suppl. 1, s. 19–26.
- 6 Walters, G. O. – Miller, F. M. – Worwood, M.: Serum ferritin concentration and iron stores in normal subjects. *J Clin Pathol*, 1973, 26, s. 233–247.
- 7 Novotný, J.: Sideropenická anemie. *Med pro praxi* 2007, 4, 11, s. 390–394.
- 8 Spangenberg, H. – Meuthen, I.: *Anemie – diferenciální diagnostika ve vnitřní lékařství*. Praha, Grada Publishing, 2010.
- 9 Hallberg, L. – Bengtsson, C. – Lapidus, I., et al.: Screening for iron deficiency. *Brit J Haematol*, 1993, 85, s. 787–798.
- 10 Muñoz, M. – Peña-Rosas, J. P. – Robinson, S., et al.: Patient blood management in obstetrics. NATA consensus statement. *Transfus Med*, 2018, 28, s. 22–39.
- 11 Eisele, L. – Durig, J. – Broecker-Preuss, M., et al.: Prevalence and incidence of anaemia in the German Heinz Nixdorf Real Study. *Ann Hematol*, 2013, 92, s. 731–737.
- 12 Zakrzewski, M. – Wilkins, S. J. – Helman, S. I., et al.: Supplementation with Sucrosomial® iron leads to favourable changes in the intestinal microbiome when compared to ferrous sulfate in mice. *Biomaterials*, 2022, 35, s. 27–38.
- 13 Fabiano, A. – Brilli, E. – Fogli, S., et al.: Sucrosomial iron absorption studied by in vitro and ex-vivo models. *Eur J Pharm Sci*, 2018, 111, s. 425–431.
- 14 Giordano, G. – Napolitano, M. – Di Battista, et al.: Oral high-dose sucrosomial iron versus intravenous iron in sideropenic anemia patients intolerant to iron sulfate. *Ann Hematol*, 2021, 100, s. 2173–2179.
- 15 Gómez-Ramírez, S. – Brilli, E. – Tarantino, G., et al.: Sucrosomial Iron: A new generation for improving oral supplementation. *Pharmaceuticals*, 2018, 11, s. 97.
- 16 Elli, L. – Ferretti, F. – Branchi, F., et al.: Sucrosomial iron supplementation in anemic patients with celiac disease not tolerating oral ferrous sulfate. *Nutrients*, 2018, 10, s. 1–9.
- 17 Ascanio, M. – Darba, M.: Economic assessment of oral Fisiogin Ferro Forte versus intravenous iron for management of iron deficiency in Crohn's disease in Spain. *Rev Exp Econ Salud*, 2019, 14, s. 406–415.
- 18 Mafodda, A. – Giuffrida, D. – Prestifilippo, A., et al.: Oral sucrosomial iron versus intravenous iron in anemic cancer patients without iron deficiency receiving darbapoetin alfa. *Support Care Cancer*, 2017, 25, s. 2776–2786.
- 19 Parisi, F. – Berti, F. – Mando, Ch., et al.: Effects of different regimens of iron prophylaxis on maternal iron status and pregnancy outcome. *J Matern Fetal Neonatal Med*, 2017, 30, s. 1787–1792.

## Klinické použití mikronizovaného progesteronu

MUDr. Petr Křepelka, Ph.D. Ústav pro péči o matku a dítě, Praha

- 1 Wakatsuki, A. – Okatani, Y. – Ikenoue, N., et al.: Effect of medroxyprogesterone acetate on endothelium-dependent vasodilation in postmenopausal women receiving estrogen. *Circulation*, 2001, 104, s. 1773–1778.
- 2 Reuben, D. B. – Palla, S. L. – Hu, P., et al.: Progesterins affect mechanism of estrogen-induced C-reactive protein stimulation. *Am J Med*, 2006, 119, s. 167.e1–8.
- 3 Gompel, A.: Micronized progesterone and its impact on the endometrium and breast vs. progestogens. *Climacteric*, 2012, 15, suppl. 1, s. 18–25.
- 4 Csapo, A. I. – Pulkkinen, M.: Indispensability of the human corpus luteum in the maintenance of early pregnancy. Luteectomy evidence. *Obstet Gynecol Surv*, 1978, 33, s. 69–81.
- 5 Peyron, R. – Aubény, E. – Targosz, V., et al.: Early termination of pregnancy with mifepristone (RU 486) and the orally active prostaglandin misoprostol. *N Engl J Med*, 1993, 328, s. 1509–1513.
- 6 Lockwood, C. J. – Stocco, C. – Murk, W., et al.: Human labor is associated with reduced decidual cell expression of progesterone, but not glucocorticoid, receptors. *J Clin Endocrinol Metab*, 2010, 95, s. 2271–2275.
- 7 Shah, N. M. – Lai, P. F. – Imami, N., et al.: Progesterone-related immune modulation of pregnancy and labor. *Front Endocrinol*, 2019, dostupné z: <https://doi.org/10.3389/fendo.2019.00198>, vyhledáno 21. 4. 2022.
- 8 Walani, S. R.: Global burden of preterm birth. *Int J Gynaecol Obstet*, 2020, 150, s. 31–33.
- 9 EPPPIC Group: Evaluating Progesterogens for Preventing Preterm Birth International Collaborative (EPPPIC): meta-analysis of individual participant data from randomised controlled trials. *Lancet*, 2021, 397, s. 1183–1194.
- 10 Hoffman, M. K.: Prediction and prevention of spontaneous preterm birth: ACOG Practice Bulletin, Number 234. *Obstet Gynecol*, 2021, 138, s. e65–e90.
- 11 SMFM Statement: Use of 17-alpha hydroxyprogesterone caproate for prevention of recurrent preterm birth. *Am J Obstet Gynecol*, 2020, 223, s. B16–B18.
- 12 Romero, R. – Conde-Agudelo, A. – Rehal, A., et al.: Vaginal progesterone for the prevention of preterm birth and adverse perinatal outcomes in twin gestations with a short cervix: an updated individual patient data meta-analysis. *Ultrasound Obstet Gynecol*, 2022, 59, s. 263–266.
- 13 Schuit, E. – Stock, S. – Rode, L., et al.: Effectiveness of progestogens to improve perinatal outcome in twin pregnancies: an individual participant data meta-analysis. *Bjog*, 2015, 122, s. 27–37.
- 14 Durnwald, C. P.: 17 OHPC for prevention of preterm birth in twins: back to the drawing board? *Am J Obstet Gynecol*, 2013, 208, s. 167–168.
- 15 Norman, J. E. – Marlow, N. – Messow, C. M., et al.: Vaginal progesterone prophylaxis for preterm birth (the OPPTIMUM study): a multicentre, randomised, double-blind trial. *Lancet*, 2016, 387, s. 2106–2116.
- 16 Zanatta, A. – Rocha, A. M. – Carvalho, F. M., et al.: The role of the Hoxa10/HOXA10 gene in the etiology of endometriosis and its related infertility: a review. *J Assist Reprod Genet*, 2010, 27, s. 701–710.
- 17 Devall, A. J. – Papadopoulos, A. – Podesek, M., et al.: Progesterogens for preventing miscarriage: a network meta-analysis. *Cochrane Database Syst Rev*, 2021, 4, CD013792.
- 18 Ectopic pregnancy and miscarriage: diagnosis and initial management. NICE guideline [NG126] Publikováno 17. 4. 2019, poslední aktualizace: 24. 11. 2021. Dostupné z: <https://www.nice.org.uk/guidance/ng126>, vyhledáno 4. 5. 2022.
- 19 ESHRE Guideline Group on RPL; Bender Atik, R. – Christiansen, O. B. – Elson, J., et al.: ESHRE guideline: recurrent pregnancy loss. *Hum Reprod Open*, 2018, doi: 10.1093/hropen/hoy004.
- 20 Stephenson, M. D., et al.: Luteal start vaginal micronized progesterone improves pregnancy success in women with recurrent pregnancy loss. *Fertil Steril*, 2017, 107, s. 684–690.
- 21 Coomarasamy, A. – Dhillon-Smith, R. K. – Papadopoulos, A., et al.: Recurrent miscarriage: evidence to accelerate action. *Lancet*, 2021, 397, s. 1675–1682.
- 22 van der Linden, M. – Buckingham, K. – Farquhar, C., et al.: Luteal phase support for assisted reproduction cycles. *Cochrane Database Syst Rev*, 2015, 2015, CD009154.
- 23 Vaisbuch, E. – de Ziegler, D. – Leong, M., et al.: Luteal-phase support in assisted reproduction treatment: real-life practices reported worldwide by an updated website-based survey. *Reprod Biomed Online*, 2014, 28, s. 330–335.
- 24 Shoham, G. – Leong, M. – Weissman, A.: A 10-year follow-up on the practice of luteal phase support using worldwide web-based surveys. *Reprod Biol Endocrinol*, 2021, 19, s. 15.
- 25 Di Guardo, F. – Midassi, H. – Racca, A., et al.: Luteal phase support in IVF: comparison between evidence-based medicine and real-life practices. *Front Endocrinol*, 2020, 11, s. 500.
- 26 Labarta, E. – Rodríguez, C.: Progesterone use in assisted reproductive technology. *Best Pract Res Clin Obstet Gynaecol*, 2020, 69, s. 74–84.
- 27 Mohammed, A. – Woad, K. J. – Mann, G. E., et al.: Evaluation of progesterone supplementation for luteal phase support in fresh in vitro fertilization cycles. *Fertil Steril*, 2019, 112, s. 491–502.

## Cholin jako esenciální živina a jeho význam v těhotenství

MUDr. Simona Mlezivová Gynekologicko-porodnická klinika 1. LF UK a Fakultní nemocnice Bulovka, Praha

prof. MUDr. Pavel Calda, CSc. Centrum fetální medicíny, Gynekologicko-porodnická klinika 1. LF UK a VFN, Praha

- 1 Greenberg, J. A. – Bell, S. J. – Guan, Y., et al.: Folic Acid supplementation and pregnancy: more than just neural tube defect prevention. *Rev Obstet Gynecol*, 2011, 4, s. 52–59.
- 2 Zeisel, S. H.: Choline: critical role during fetal development and dietary requirements in adults. *Annu Rev Nutr*, 2006, 26, s. 229–250.
- 3 Nazki, F. H. – Sameer, A. S. – Ganaie, B. A.: Folate: Metabolism, genes, polymorphisms and the associated diseases. *Gene*, 2014, 533, s. 11–20.
- 4 Masih, S. P. – Plumpré, L. – Ly, A., et al.: Pregnant Canadian women achieve recommended intakes of one-carbon nutrients through prenatal supplementation but the supplement composition, including choline, requires reconsideration. *J Nutr*, 2015, 145, s. 1824–1834.
- 5 Leermakers, E. T. M. – Moreira, E. M. – Kieffe-De Jong, J. C., et al.: Effects of choline on health across the life course: a systematic review. *Nutr Rev*, 2015, 73, s. 500–522.
- 6 Gaskins, A. J. – Rich-Edwards, J. W. – Hauser, R., et al.: Maternal prepregnancy folate intake and risk of spontaneous abortion and stillbirth. *Obstet Gynecol*, 2014, 124, s. 23–31.
- 7 Zeisel, S. H.: Nutrition in pregnancy: The argument for including a source of choline. *Int J Womens Health*, 2013, 5, s. 193–199.
- 8 Ueland, P. M. – Holm, P. I. – Hustad, S.: Betaine: A key modulator of one-carbon metabolism and homocysteine status. *Clin Chem Lab Med*, 2005, 43, s. 1069–1075.
- 9 Michel, V. – Yuan, Z. – Ramsbriar, S., et al.: Choline transport for phospholipid synthesis. *Exp Biol Med*, 2006, 231, s. 490–504.
- 10 Sarter, M. – Parikh, V.: Choline transporters, cholinergic transmission and cognition. *Nat Rev Neurosci*, 2005, 6, s. 48–56.
- 11 Jiang, X. – Bar, H. Y. – Yan, J., et al.: A higher maternal choline intake among third-trimester pregnant women lowers placental and circulating concentrations of the antiangiogenic factor fms-like tyrosine kinase-1 (sFLT1). *FASEB J*, 2013, 27, s. 1245–1253.
- 12 Cho, E. – Willett, W. C. – Colditz, G. A., et al.: Dietary choline and betaine and the risk of distal colorectal adenoma in women. *J Natl Cancer Inst*, 2007, 99, s. 1224–1231.
- 13 Zeisel, S. H.: Choline: Human Requirements and Effects on Human Performance. In: Institute of Medicine (US) Committee on Military Nutrition Research, Marriott, B. M., eds: *Food Components to Enhance Performance*. Washington (DC), National Academies Press, 1994.
- 14 Yao, Z. – Vance, D. E.: Reduction in VLDL, but not HDL, in plasma of rats deficient in choline. *Biochem Cell Biol*, 1990, 68, s. 552–558.
- 15 Da Costa, K. A. – Badesa, M. – Fischer, L. M., et al.: Elevated serum creatinine phosphokinase in choline-deficient humans: mechanistic studies in C2C12 mouse myoblasts. *Am J Clin Nutr*, 2004, 80, s. 163–170.
- 16 Rees, W. D. – Wilson, F. A. – Maloney, C. A.: Sulfur amino acid metabolism in pregnancy: The impact of methionine in the maternal diet. *J Nutr*, 2006, 136, s. 1701S–1705S.
- 17 Buchman, A. L. – Awal, M. – Jenden, D., et al.: The effect of lecithin supplementation on plasma choline concentrations during

- a marathon. *J Am Coll Nutr*, 2000, 19, s. 768–770.
- 18 Zeisel, S. H. – Da Costa, K. A. – Franklin, P. D., et al.: Choline, an essential nutrient for humans. *FASEB J*, 1991, 5, s. 2093–2098.
  - 19 Romano, K. A. – Vivas, E. I. – Amador-Noguez, D., et al.: Intestinal microbiota composition modulates choline bioavailability from diet and accumulation of the proatherogenic metabolite trimethylamine-N-oxide. *MBio*, 2015, 6, s. e02481–414.
  - 20 Zeisel, S. H. – Warriar, M.: Trimethylamine N-oxide, the microbiome, and heart and kidney disease. *Annu Rev Nutr*, 2017, 37, s. 157–181.
  - 21 Wang, Y. – Surzenko, N. – Friday, W. B., et al.: Maternal dietary intake of choline in mice regulates development of the cerebral cortex in the offspring. *FASEB J*, 2016, 30, s. 1566–1578.
  - 22 Tang, W. H. W. – Wang, Z. – Levison, B. S., et al.: Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. *N Engl J Med*, 2013, 368, s. 1575–1584.
  - 23 Bae, S. – Ulrich, C. M. – Neuhouser, M. L., et al.: Plasma choline metabolites and colorectal cancer risk in the women's health initiative observational study. *Cancer Res*, 2014, 74, s. 7442–7452.
  - 24 Resseguie, M. – Song, J. – Niculescu, M. D., et al.: Phosphatidylethanolamine N-methyltransferase (PEMT) gene expression is induced by estrogen in human and mouse primary hepatocytes. *FASEB J*, 2007, 21, s. 2622–2632.
  - 25 Fischer, L. M. – da Costa, K. A. – Kwock, L., et al.: Dietary choline requirements of women: effects of estrogen and genetic variation. *Am J Clin Nutr*, 2010, 92, s. 1113–1119.
  - 26 da Silva, R. P. – Kelly, K. B. – Lewis, E. D., et al.: Choline deficiency impairs intestinal lipid metabolism in the lactating rat. *J Nutr Biochem*, 2015, 26, s. 1077–1083.
  - 27 Zeisel, S. H. – Mar, M. H. – Zhou, Z., et al.: Pregnancy and lactation are associated with diminished concentrations of choline and its metabolites in rat liver. *J Nutr*, 1995, 125, s. 3049–3054.
  - 28 Kim, Y. I. – Miller, J. W. – Da Costa, K. A., et al.: Severe folate deficiency causes secondary depletion of choline and phosphocholine in rat liver. *J Nutr*, 1994, 124, s. 2197–2203.
  - 29 Abratte, C. M. – Wang, W. – Li, R., et al.: Folate intake and the MTHFR C677T genotype influence choline status in young Mexican American women. *J Nutr Biochem*, 2008, 19, s. 158–165.
  - 30 Saffery, R. – Novakovic, B.: Epigenetics as the mediator of fetal programming of adult onset disease: what is the evidence? *Acta Obstet Gynecol Scand*, 2014, 93, s. 1090–1098.
  - 31 Langley-Evans, S. C. – Bellinger, L. – McMullen, S.: Animal models of programming: early life influences on appetite and feeding behaviour. *Matern Child Nutr*, 2005, 1, s. 142–148.
  - 32 Wilkins, J. F.: Genomic imprinting and methylation: Epigenetic canalization and conflict. *Trends Genet*, 2005, 21, s. 356–365.
  - 33 Cooney, C. A. – Dave, A. A. – Wolff, G. L.: Maternal methyl supplements in mice affect epigenetic variation and DNA methylation of offspring. *J Nutr*, 2002, 132, suppl. 8, s. 2393S–2400S.
  - 34 Cropley, J. E. – Dang, T. H. Y. – Martin, D. I. K., et al.: The penetrance of an epigenetic trait in mice is progressively yet reversibly increased by selection and environment. *Proc Biol Sci*, 2012, 279, s. 2347–2353.
  - 35 Cropley, J. E. – Suter, C. M. – Beckman, K. B., et al.: Germ-line epigenetic modification of the murine Avy allele by nutritional supplementation. *Proc Natl Acad Sci U S A*, 2006, 103, s. 17308–17312.
  - 36 Dolinoy, D. C.: The agouti mouse model: an epigenetic biosensor for nutritional and environmental alterations on the fetal epigenome. *Nutr Rev*, 2008, 66, suppl. 1, s. S7–S11.
  - 37 Maloney, C. A. – Hay, S. M. – Rees, W. D.: Folate deficiency during pregnancy impacts on methyl metabolism without affecting global DNA methylation in the rat fetus. *Br J Nutr*, 2007, 97, s. 1090–1098.
  - 38 Chmurzynska, A. – Młodzik, M. A. – Radziejewska, A., et al.: Caloric restriction can affect one-carbon metabolism during pregnancy in the rat: A transgenerational model. *Biochimie*, 2018, 152, s. 181–187.
  - 39 Nowacka-Wozzuk, J. – Szczerbal, I. – Malinowska, A. M., et al.: Trans-generational effects of prenatal restricted diet on gene expression and histone modifications in the rat. *PLoS One*, 2018, 13, s. e0193464.
  - 40 Devés, R. – Krupka, R. M.: The binding and translocation steps in transport as related to substrate structure. A study of the choline carrier of erythrocytes. *BBA – Biomembr*, 1979, 557, s. 469–485.
  - 41 Caldenhove, S. – Borghans, L. G. J. M. – Blokland, A., et al.: Role of acetylcholine and serotonin in novelty processing using an oddball paradigm. *Behav Brain Res*, 2017, 331, s. 199–204.
  - 42 Batool, Z. – Sadir, S. – Liaquat, L., et al.: Repeated administration of almonds increases brain acetylcholine levels and enhances memory function in healthy rats while attenuates memory deficits in animal model of amnesia. *Brain Res Bull*, 2016, 120, s. 63–74.
  - 43 Apparsundaram, S. – Ferguson, S. M. – George, A. L., et al.: Molecular cloning of a human, hemicholinium-3-sensitive choline transporter. *Biochem Biophys Res Commun*, 2000, 276, s. 862–867.
  - 44 Ferguson, S. M. – Bazalakova, M. – Savchenko, V., et al.: Lethal impairment of cholinergic neurotransmission in hemicholinium-3-sensitive choline transporter knockout mice. *Proc Natl Acad Sci U S A*, 2004, 101, s. 8762–8767.
  - 45 Bauché, S. – O'Regan, S. – Azuma, Y., et al.: Impaired presynaptic high-affinity choline transporter causes a congenital myasthenic syndrome with episodic apnea. *Am J Hum Genet*, 2016, 99, s. 753–761.
  - 46 Schara, U. – Lochmüller, H.: Therapeutic strategies in congenital myasthenic syndromes. *Neurotherapeutics*, 2008, 5, s. 542–547.
  - 47 Eymard, B. – Stojković, T. – Sternberg, D., et al.: Syndromes myasthéniques congénitaux: difficultés diagnostiques, évolution et pronostic, thérapeutique L'expérience du réseau national « Syndromes Myasthéniques Congénitaux ». *Revue Neurologique*, 2013, 169, suppl. 1, s. S45–S55.
  - 48 Keller, M. – Chance, P.: Inherited peripheral neuropathy. *Semin Neurol*, 1999, 19, s. 353–362.
  - 49 Barwick, K. E. S. – Wright, J. – Al-Turki, S., et al.: Defective presynaptic choline transport underlies hereditary motor neuropathy. *Am J Hum Genet*, 2012, 91, s. 1103–1107.
  - 50 Sweiry, J. H. – Yudilevich, D. L.: Characterization of choline transport at maternal and fetal interfaces of the perfused guinea-pig placenta. *J Physiol*, 1985, 366, s. 251–266.
  - 51 Jarosz, M.: Normy żywienia dla populacji Polski redakcja naukowa. Dostępne z: [www.izz.waw.pl/en/normy-zwienia](http://www.izz.waw.pl/en/normy-zwienia), vyhledáno 30. 5. 2020.
  - 52 Scientific Opinion on Dietary Reference Values for folate. *EFSA J*, 2014, 12, s. 3893.
  - 53 Patterson, K. Y. – Bhagwat, S. A. – Williams, J. R., et al.: USDA Database for the Choline Content of Common Foods. 2008, dostupné z: [www.ars.usda.gov/ARSUserFiles/80400525/data/choline/choln02.pdf](http://www.ars.usda.gov/ARSUserFiles/80400525/data/choline/choln02.pdf), vyhledáno 11. 5. 2022.
  - 54 Zeisel, S. H. – da Costa, K. A.: Choline: an essential nutrient for public health. *Nutr Rev*, 2009, 67, s. 615–623.
  - 55 Vennemann, F. B. C. – Ioannidou, S. – Valsta, L. M., et al.: Dietary intake and food sources of choline in European populations. *Br J Nutr*, 2015, 114, s. 2046–2055.
  - 56 Scazzone, C. – Bono, A. – Tornese, F., et al.: Correlation between low folate levels and hyperhomocysteinemia, but not with vitamin B12 in hypertensive patients. *Ann Clin Lab Sci*, 2014, 44, s. 286–290.
  - 57 Zeisel, S. H.: Advisory board: The importance of choline during pregnancy and breastfeeding: choline key roles in pregnancy. Interview, 2019.

## Sildenafil možným přínosem v léčbě Alzheimerovy choroby?

doc. MUDr. Jiří Slíva, Ph.D. Ústav farmakologie, 3. LF UK, Praha

- 1 Lei, P. – Ayton, S. – Bush, A. I.: The essential elements of Alzheimer's disease. *J Biol Chem*, 2021, 296, s. 100105.
- 2 Doifode, T. – Giridharan, V. V. – Generoso, J. S., et al.: The impact of the microbiota-gut-brain axis on Alzheimer's disease pathophysiology. *Pharmacol Res*, 2021, 164, s. 105314.
- 3 Scheltens, P. – De Strooper, B. – Kivipelto, M., et al.: Alzheimer's disease. *Lancet*, 2021, 397, s. 1577–1590.
- 4 Honig, L. S. – Vellas, B. – Woodward, M., et al.: Trial of solanezumab for mild dementia due to Alzheimer's disease. *N Engl J Med*, 2018, 378, s. 321–330.
- 5 Rabinovici, G. D.: Controversy and progress in Alzheimer's disease – FDA approval of aducanumab. *N Engl J Med*, 2021, 385, s. 771–774.
- 6 Liu, P. – Fleete, M. S. – Jing, Y., et al.: Altered arginine metabolism in Alzheimer's disease brains. *Neurobiol Aging*, 2014, 35, s. 1992–2003.
- 7 Lüth, H. J. – Münch, G. – Arendt, T.: Aberrant expression of NOS isoforms in Alzheimer's disease is structurally related to nitrotyrosine formation. *Brain Res*, 2002, 953, s. 135–143.
- 8 Ugarte, A. – Gil-Bea, F. – García-Barroso, C., et al.: Decreased level of guanosine 3', 5'-monophosphate (cGMP) in cerebrospinal fluid (CSF) are associated with cognitive decline and amyloid pathology in Alzheimer's disease. *Neuropathol Appl Neurobiol*, 2015, 41, s. 471–482.
- 9 Hesse, R. – Lausser, L. – Gummert, P., et al.: Reduced cGMP levels in CSF of AD patients correlate with severity of dementia and current depression. *Alzheimers Res Ther*, 2017, 9, s. 17.
- 10 Sanders, O.: Sildenafil for the treatment of Alzheimer's disease: a systematic review. *J Alzheimers Dis Rep*, 2020, 4, s. 91–106.
- 11 Zhang, R. – Wang, Y. – Zhang, L., et al.: Sildenafil (Viagra) induces neurogenesis and promotes functional recovery after stroke in rats. *Stroke*, 2002, 33, s. 2675–2680.
- 12 Ramirez, C. E. – Nian, H. – Yu, C., et al.: Treatment with sildenafil improves insulin sensitivity in prediabetes: a randomized, controlled trial. *J Clin Endocrinol Metab*, 2015, 100, s. 4533–4540.
- 13 Aversa, A. – Vitale, C. – Volterrani, M., et al.: Chronic administration of sildenafil improves markers of endothelial function in men with type 2 diabetes. *Diabet Med*, 2008, 25, s. 37–44.
- 14 Sheng, M. – Lu, H. – Liu, P., et al.: Sildenafil improves vascular and metabolic function in patients with Alzheimer's disease. *J Alzheimers Dis*, 2017, 60, s. 1351–1364.
- 15 Wong, A. – Zhang, Y. W. – Jeschke, G. R., et al.: Cyclic GMP-dependent stimulation of serotonin transport does not involve direct transporter phosphorylation by cGMP-dependent protein kinase. *J Biol Chem*, 2012, 287, s. 36051–8.
- 16 Nurnberg, H. G. – Seidman, S. N. – Gelenberg, A. J., et al.: Depression, antidepressant therapies, and erectile dysfunction: clinical trials of sildenafil citrate (Viagra) in treated and untreated patients with depression. *Urology*, 2002, 60, suppl. 2, s. 58–66.